Teladoc Health, Inc.
NYSE:TDOCMedical - Healthcare Information Services
+$0.20 today
- Market cap
- $1.47B
- Beta
- 2.14
- P/E (TTM)
- -8.1
- EPS (TTM)
- -$0.96
Volume 3.96M
Average 4.68M
TDOC Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Teladoc Health, Inc.NYSE: TDOC
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $14.61M fell 41.9% year over year, ahead of the -45.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 8.2% from the prior quarter. Over 3 fiscal years it compounded at -28.3% a year.
Context
- Stock-based compensation amounted to 3.2% of revenue in FY2025, down 2.5 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -41.9% holds above the trailing-twelve-month pace of -45.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 80.41M USD
- Year-over-year change
- -44.9%
- 4-year CAGR
- -28.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 80.41M | -44.9% |
| FY2024 | 2024-12-31 | 145.95M | -27.6% |
| FY2023 | 2023-12-31 | 201.55M | -7.5% |
| FY2022 | 2022-12-31 | 217.85M | -28.0% |
| FY2021 | 2021-12-31 | 302.59M | — |
Stock-Based Compensation vs competitors
How TDOC compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -45.8% is the lowest of 10, against a peer median of -7.1%.
- Stock-based compensation amounts to 2.8% of revenue for TDOC, versus a peer median of 7.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $126.89M USD | -1.6% | +9.4% | 9.7% | |
| LTM Mar 2026 | $118.47M USD | -23.8% | — | 17.6% | |
| LTM Mar 2026 | $69.86M USD | -45.8% | -28.3% | 2.8% | |
| LTM Apr 2026 | $63.78M USD | -5.3% | +4.7% | 12.9% | |
| LTM Sep 2026 | $37.41M USD | +60.8% | +68.9% | — | |
| LTM Sep 2026 | $35.75M USD | -21.5% | +2.8% | 13.3% | |
| LTM Mar 2026 | $31.24M USD | -24.7% | -13.3% | 2.5% | |
| LTM Sep 2026 | €17.97M EUR | -7.1% | +18.8% | — | |
| LTM Mar 2026 | $14.32M USD | +52.4% | +24.9% | 5.1% | |
| LTM Sep 2026 | $12.24M USD | -41.4% | +9.3% | 2.0% | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding TDOC) | — | -7.1% | +9.3% | 7.4% | |
Competitors are the stored peer set for TDOC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (428.79M) | (13.66B) | (220.37M) | (1B) | (200.32M) |
| Depreciation & Amortization | 219.62M | 267.78M | 348.72M | 382.84M | 363.12M |
| Deferred Income Tax | 41.8M | (7.84M) | (1.9M) | (1.15M) | (41.41M) |
| Stock-Based Compensation | 302.59M | 217.85M | 201.55M | 145.95M | 80.41M |
| Change in Working Capital | (43.99M) | (48.39M) | 11.64M | (36.32M) | 1.08M |
| Accounts Receivables | (11.17M) | (49.06M) | (10.25M) | (375K) | 25.13M |
| Inventory | (19.49M) | 14.8M | 24.1M | (9.75M) | 399K |
| Accounts Payables | 1.19M | 1.88M | (4.19M) | (10.37M) | 11.45M |
| Other Working Capital | (14.51M) | (16.01M) | 1.99M | (15.83M) | (35.9M) |
| Other Non-Cash Items | 102.76M | 13.42B | 10.38M | 803.59M | 91.48M |
| Operating Cash Flow | 193.99M | 189.29M | 350.02M | 293.68M | 294.36M |
| Capital Expenditures | (8.53M) | (16.48M) | (156.35M) | (10.79M) | (8.89M) |
| Acquisitions (Net) | (78.66M) | 0 | 0 | 0 | (81.9M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 60.9M | 2.51M | 0 | 0 | 740K |
| Other Investing Activities | 8.72M | 2.51M | 1K | (113.26M) | (175.95M) |
| Investing Cash Flow | (72.98M) | (167.74M) | (156.35M) | (124.05M) | (266M) |
| Debt Repayment | (914K) | (3.15M) | 0 | 0 | (550.63M) |
| Common Stock Issued | 42.59M | 12.39M | 11.13M | 8.31M | 3.09M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (730K) | (2.74M) | (278K) | (2K) | (4.11M) |
| Financing Cash Flow | 40.95M | 6.5M | 10.85M | 8.31M | (551.65M) |
| Effect of Forex Changes | (1.8M) | (3.34M) | 965K | (3.29M) | 6.06M |
| Net Change in Cash | 160.16M | 24.7M | 205.49M | 174.65M | (517.24M) |
| Free Cash Flow | 185.46M | 172.81M | 193.67M | 282.89M | 285.46M |
Teladoc Health, Inc.
NYSE:TDOC
Intrinsic Alpha fair value
Locked
Current Price
$8.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.